- Home
- RNAZ vs ISPC Comparison
RNAZ vs ISPC Comparison
Compare RNAZ & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNAZ | ISPC |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 4.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RNAZ | ISPC |
|---|---|---|
| Price | $1.65 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.5K | ★ 439.6K |
| Earning Date | 08-14-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.03 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,928,998.00 |
| Revenue This Year | N/A | $638.10 |
| Revenue Next Year | N/A | $17.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $0.10 |
| 52 Week High | $20.99 | $6.77 |
Technical Indicators
Market Signals| Indicator | RNAZ | ISPC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 27.64 |
| Support Level | N/A | $0.27 |
| Resistance Level | N/A | $1.94 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 6.29 |
Price Performance
Historical ComparisonAbout RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.